The purpose of this study is to identify genetic predictors of lithium response in bipolar disorder.

Condition	Intervention
Bipolar Disorder	Drug: Lithium treatment

Further study details as provided by Department of Veterans Affairs:

Expected Total Enrollment:  200

The long term focus of this research program has been identification of genes for bipolar disorder. We have recently obtained evidence from several lines of investigation to support the role of the gene for G protein receptor Kinase 3(GRK3) in bipolar disorder. Work to replicate and extend these results is continuing under NIH funding. In this clinical we will extend our work into Pharmacogenetics to attempt to identify genes that are associated with medication response in bipolar disorder. Lithium is the first mood stabilizer medication and remains a mainstay of treatment. Many patients have an excellent response to lithium, tolerate it well, and are stabilized for years, while others do not. The reasons for this difference in response are unclear, but it is likely that genetic factors make a substantial contribution. The lack of good predictors of response frequently result in a time consuming trial and error clinical process to find the best medication. Such a trial and error process can take months with prolongation of patient suffering. Hence, there is a strong clinical need for predictors. We have conducted a preliminary study with 92 lithium responders and 92 non-responders identified through retrospective detailed history and chart review. These subjects have been genotyped at 88 SNP markers in 9 candidates genes relevant to lithium presumed mechanism of action for bipolar disorder. Four SNP markers in three genes showed nominally significant association to lithium response. One of the SNPs in the gene for NTRK2, the receptor for BDNF, Showed a strong association in patients who had predominantly euphoric a opposed to dyshoric mania (p=0.0005). Many data argue for the role of BDNF in the mechanism of antidepressants and mood stabilized action as well as susceptibility to bipolar disorder. No association was observed in those with dysphoric mania. This suggests that variations in this gene may operate in a cinically and genetically distinct subset of patients. It also argues for the importance of incorporating clinical subtypes into such analyses. These pilot results are preliminary but suggest the feasibility of such an approach. We will conduct a prospective trial of lithium monotherapy in 100 patients with bipolar disorder. 200 patients who are unstable, mildly to moderately ill and not on lithium will be screened and then entered into 16-week stabilization phase where they will be treated and switched to lithium monotherapy. Patient stable on lithium will also be entered and other mediations withdrawn. After stabilization patients will be followed for one year or until a mood episode requires intervention. It is expected that 50% of patients will be stabilized and therefore 100 patients will enter the maintenance phase. Time to relapse and pharmological intervention will be the primary outcome measure. This prospective sample will be used to replicate previous reults at the NTRK2 and other genes. Analyses will be conducted to test for differences in survival curves between different genotypic group. Genomic control methods will be employed to detect or correct for possible stratification and heterogeneity. Clinical featurees of illness such as dysphoric mania, family history and rapid cycling will be employed as co-variates. Multivariate methods will also be employed in order to attempt to develope a multi-gene predictor of lithium response.

Ages Eligible for Study:  21 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

1. Are 18 years of age or older;
2. Have a diagnosis of Bipolar Affective Disorder, I or II;
3. Have no contraindications, allergies, or previous adverse events or treatment failures with lithium;
4. Women who are not currently pregnant and are willing and able to use bith control;
5. Are clinically appropriate to treat with lithium.

Exclusion Criteria:

1. DSM-IV Axis I Diagnosis: other primary comorbid axis I disorders such as: schizophrenia, schizoaffective disorder, delusional disorder;
2. Alcohol or Substance Deprendence: meets criteria for dependence within past 3 months;
3. Unstable Medial Conditions: Life threatening or unstable medical condition that require active adjustment of medications by medical history; or
4. Medical Conditions: concomitant medical condition that would preclude the use of lithium (i.e.: renal failure, head truama with loss of consciousness, or clinically significant cardiac, renal, hepatic, neoplastic, or cardiovascular disease);
5. Concomitant treatment with the following medications (during maintenance Phase): antipsychotics, antidepressants, antianxiety agent with the exception of benzodiazepines, to be used if needed for anxiety or insomia, not to exceed 10 doses/week, or mood stabilizers with the exception of lithium; and
6. Active suicidal or homicidal ideations as elicited in the interviews.
7. Stable and doing well on a mood stabilizer other than lithium.

Please refer to this study by ClinicalTrials.gov identifier  NCT00252577

Susan Leckband, R.Ph      858-535-4786    susan.leckband@med.va.gov

California
      VA SAn Diego Healthcare System, San Diego,  California,  92161,  United States

Study chairs or principal investigators

John R. Kelsoe, MD,  Principal Investigator,  Staff Physician   

Study ID Numbers:  MHBA-023-05S
Last Updated:  December 8, 2005
Record first received:  November 9, 2005
ClinicalTrials.gov Identifier:  NCT00252577
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2006-01-10